MX2019014584A - Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas. - Google Patents

Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas.

Info

Publication number
MX2019014584A
MX2019014584A MX2019014584A MX2019014584A MX2019014584A MX 2019014584 A MX2019014584 A MX 2019014584A MX 2019014584 A MX2019014584 A MX 2019014584A MX 2019014584 A MX2019014584 A MX 2019014584A MX 2019014584 A MX2019014584 A MX 2019014584A
Authority
MX
Mexico
Prior art keywords
cells
methods
making
reduced surface
same
Prior art date
Application number
MX2019014584A
Other languages
English (en)
Spanish (es)
Inventor
Gardai Shyra
Heiser Ryan
Okeley Nicole
Field Jessica
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2019014584A publication Critical patent/MX2019014584A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MX2019014584A 2017-06-07 2018-06-05 Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas. MX2019014584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
PCT/US2018/036067 WO2018226701A1 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Publications (1)

Publication Number Publication Date
MX2019014584A true MX2019014584A (es) 2020-02-07

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014584A MX2019014584A (es) 2017-06-07 2018-06-05 Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas.

Country Status (17)

Country Link
US (2) US11891644B2 (enExample)
EP (1) EP3634427A1 (enExample)
JP (1) JP7245177B2 (enExample)
KR (1) KR102687149B1 (enExample)
CN (1) CN110740734A (enExample)
AU (1) AU2018282225B2 (enExample)
BR (1) BR112019025775A2 (enExample)
CA (1) CA3065524A1 (enExample)
EA (1) EA201992875A1 (enExample)
IL (1) IL271012B2 (enExample)
MA (1) MA50865A (enExample)
MX (1) MX2019014584A (enExample)
SG (1) SG11201911617SA (enExample)
TW (1) TW201903144A (enExample)
UA (1) UA128783C2 (enExample)
WO (1) WO2018226701A1 (enExample)
ZA (1) ZA201907623B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
PT3102609T (pt) 2014-02-04 2024-10-23 Us Health Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
MX2017003062A (es) 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc Methods of preparing T cells for T cell therapy
SG11201804263PA (en) * 2015-12-04 2018-06-28 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Also Published As

Publication number Publication date
CN110740734A (zh) 2020-01-31
JP7245177B2 (ja) 2023-03-23
CA3065524A1 (en) 2018-12-13
US20240117400A1 (en) 2024-04-11
EP3634427A1 (en) 2020-04-15
IL271012B2 (en) 2023-12-01
JP2020523014A (ja) 2020-08-06
US11891644B2 (en) 2024-02-06
EA201992875A1 (ru) 2020-03-25
WO2018226701A1 (en) 2018-12-13
KR20200015580A (ko) 2020-02-12
TW201903144A (zh) 2019-01-16
MA50865A (fr) 2020-04-15
ZA201907623B (en) 2024-04-24
US20200149082A1 (en) 2020-05-14
KR102687149B1 (ko) 2024-07-24
SG11201911617SA (en) 2020-01-30
IL271012A (en) 2020-01-30
UA128783C2 (uk) 2024-10-23
BR112019025775A2 (pt) 2020-06-23
AU2018282225A1 (en) 2019-12-12
AU2018282225B2 (en) 2024-06-13
IL271012B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
PT3886875T (pt) Métodos para tratamento utilizando terapia celular adotiva
MX374501B (es) Formulaciones de anticuerpos de her2 subcutáneas.
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX380555B (es) Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX389749B (es) Sistemas y métodos para el uso simultáneo del espectro dentro del espectro usado activamente.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
MX387916B (es) Constructo de expresión para la producción transitoria de una proteína terapéutica casp9 en una célula objetivo senescente humana.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX380204B (es) Micrordenamiento para suministro de agente terapeútico y métodos de uso.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112015030972A8 (pt) células sc-beta e composições e métodos para geração das mesmas
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX375838B (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2020000734A1 (es) Expansión y uso de fracciones de células nk ampliadas.
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.